ONWARD Medical Reports 430% ARC-EX Sales Surge, Secures $50M…

Event summary

ONWARD Medical sold 159 ARC-EX Systems in H1 2026, up 430% YoY, with expanded home-use access in US Veterans Affairs system.
Company raised EUR 40.6M in equity capital and secured up to EUR 50M debt financing facility from BlackRock.
First participant enrolled in Empower BP global pivotal study for ARC-IM System, with 22 participants enrolled across 14 sites.
Initiated EIGER clinical feasibility study for ARC-IM System to restore mobility in spinal cord injury patients.
Reported EUR 4.2M in total revenue, with ARC-EX System revenue growing 240% YoY to EUR 3.4M.

The big picture

ONWARD Medical's strong H1 2026 results highlight the growing demand for its ARC-EX System, particularly in home-use settings. The company's ability to secure significant financing from BlackRock and EQT Life Sciences underscores investor confidence in its neurotechnology pipeline. As ONWARD advances its ARC-IM and ARC-BCI platforms through clinical trials, its strategic positioning in the spinal cord injury and movement disability market becomes increasingly competitive. The company's focus on expanding commercial reach and securing regulatory milestones will be critical in sustaining its growth trajectory.

What we're watching

Commercial Expansion: How ONWARD Medical will scale ARC-EX System adoption beyond US clinics into European markets and home settings.
Regulatory Progress: The pace at which ARC-IM System advances through pivotal studies toward potential regulatory approval.
Financial Flexibility: Whether ONWARD Medical's strengthened balance sheet and BlackRock debt facility will support aggressive pipeline investments.